Cdh19, a cell adhesion protein, is involved in various biological processes. It plays a role in cell-cell adhesion and is associated with multiple signaling pathways. Its function is crucial for normal development, especially in neural crest cell migration, and has implications in disease-related processes such as cancer progression [1,2,3,4,5,6,7,8,9,10].

In cervical carcinoma, CDH19 expression is downregulated, and overexpression of CDH19 inhibits cell proliferation and suppresses the activation of AKT and NF-κB signaling pathways, suggesting it may be a potential therapeutic target [1]. In gastric cancer, knocking down CDH19 affects the transcription levels of ACSL4 and GPX4, increases intracellular iron ion concentration and ROS accumulation, and inhibits cell proliferation and migration, identifying it as a possible therapeutic target [3]. In the development of the enteric nervous system, Cdh19 is a direct target of Sox10 during early sacral neural crest cell migration. Knockdown of Cdh19 results in retarded sacral neural crest cell migration in vitro and ex vivo [8].

In conclusion, Cdh19 is essential for cell adhesion and neural crest cell migration during development. Its dysregulation is implicated in cancers like cervical and gastric cancer. The findings from gene-manipulation studies, especially those involving knockdown or overexpression, provide insights into its role in disease, suggesting Cdh19 could be a valuable target for therapeutic intervention in related disease areas.